Patents by Inventor Deb K. Chatterjee
Deb K. Chatterjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230257775Abstract: Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.Type: ApplicationFiled: February 24, 2023Publication date: August 17, 2023Inventors: Deb K. Chatterjee, Stanislaw J. Kaczmarczyk
-
Patent number: 11718861Abstract: Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.Type: GrantFiled: December 14, 2020Date of Patent: August 8, 2023Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Deb K. Chatterjee, Stanislaw J. Kaczmarczyk
-
Publication number: 20210163988Abstract: Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.Type: ApplicationFiled: December 14, 2020Publication date: June 3, 2021Inventors: Deb K. Chatterjee, Stanislaw J. Kaczmarczyk
-
Publication number: 20200102545Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.Type: ApplicationFiled: December 10, 2019Publication date: April 2, 2020Inventors: Stanislaw J. Kaczmarczyk, Deb K. Chatterjee
-
Patent number: 10538743Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.Type: GrantFiled: June 23, 2016Date of Patent: January 21, 2020Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stanislaw J. Kaczmarczyk, Deb K. Chatterjee
-
Patent number: 9506041Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.Type: GrantFiled: March 15, 2013Date of Patent: November 29, 2016Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stanislaw J Kaczmarczyk, Deb K. Chatterjee
-
Publication number: 20160340653Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.Type: ApplicationFiled: June 23, 2016Publication date: November 24, 2016Inventors: Stanislaw J. Kaczmarczyk, Deb K. Chatterjee
-
Publication number: 20160312242Abstract: Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.Type: ApplicationFiled: December 16, 2014Publication date: October 27, 2016Inventors: Deb K. CHATTERJEE, Stanislaw J. KACZMARCZYK
-
Publication number: 20150050243Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.Type: ApplicationFiled: March 15, 2013Publication date: February 19, 2015Inventors: Stanislaw J. Kaczmarczyk, Deb K. Chatterjee
-
Publication number: 20140097086Abstract: The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies thereby facilitating rapid isolation and purification of recombinant proteins. The invention further provides methods for producing protein molecular weight ladders for us in protein gel electrophoresis, as well as proteins and protein molecular weight ladders produced by these methods.Type: ApplicationFiled: July 25, 2013Publication date: April 10, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Deb K. CHATTERJEE, Mary Longo, Elizabeth Flynn, Robert Oberfelder
-
Patent number: 8389681Abstract: The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such as E. coli thioredoxin or a modified E. coli thioredoxin, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies. The methods of the present invention facilitate the rapid isolation and purification of recombinant proteins. In addition, the present methods may be useful for producing polypeptides or proteins which are small and are typically difficult to express, as well as those proteins that are toxic to host cells such as E. coli. The present invention also provides plasmids, vectors and host cells to be used in the present invention for production of polypeptides, and methods of production of polypeptides using these vectors and host cells.Type: GrantFiled: December 29, 2006Date of Patent: March 5, 2013Assignee: Life Technologies CorporationInventors: Deb K. Chatterjee, Mary Longo, Elizabeth Flynn, Robert Oberfelder
-
Publication number: 20120184017Abstract: The present invention relates to mutant DNA polymerases which incorporate dideoxynucleotides with about the same efficiency as deoxynucleotides. The present invention also related to mutant DNA polymerases which also have substantially reduced 5?-to-3? exonuclease activity or 3?-to-5? exonuclease activity. The invention also relates to DNA molecules coding for the mutant DNA polymerases, and hosts containing the DNA molecules.Type: ApplicationFiled: December 23, 2011Publication date: July 19, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventor: Deb K. Chatterjee
-
Patent number: 8148302Abstract: The invention provides a microarray and methods for producing a protein microarray. The array comprises multiple nucleic acid molecules immobilized on a substrate, each comprising (i) a protein-binding domain and (ii) a nucleic acid sequence encoding a fusion protein comprising a polypeptide of interest and a DNA-binding protein that binds the protein-binding domain, and one or more fusion proteins produced from the multiple nucleic acid molecules. Each fusion protein is immobilized on the substrate via binding to a nucleic acid sequence comprising the protein-binding domain present on the nucleic acid molecule from which the fusion protein is produced or on the substrate. The invention also provides a method of analyzing protein interactions with, for example, other proteins, lipids and drugs.Type: GrantFiled: October 19, 2005Date of Patent: April 3, 2012Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Deb K Chatterjee, Kalavathy Sitaraman, James L Hartley, Cassio Baptista, David J Munroe
-
Patent number: 8043816Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: GrantFiled: May 18, 2009Date of Patent: October 25, 2011Assignee: Life Technologies CorporationInventors: Mekbib Astatke, Deb K. Chatterjee, Gary F. Gerard
-
Publication number: 20110250672Abstract: The present invention relates to mutant DNA polymerases which incorporate dideoxynucleotides with about the same efficiency as deoxynucleotides. The present invention also related to mutant DNA polymerases which also have substantially reduced 5?-to-3? exonuclease activity or 3?-to-5? exonuclease activity. The invention also relates to DNA molecules coding for the mutant DNA polymerases, and hosts containing the DNA molecules.Type: ApplicationFiled: April 1, 2011Publication date: October 13, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventor: Deb K. Chatterjee
-
Patent number: 8012715Abstract: The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such as E. coli thioredoxin or a modified E. coli thioredoxin, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies. The methods of the present invention facilitate the rapid isolation and purification of recombinant proteins. In addition, the present methods may be useful for producing polypeptides or proteins which are small and are typically difficult to express, as well as those proteins that are toxic to host cells such as E. coli. The present invention also provides plasmids, vectors and host cells to be used in the present invention for production of polypeptides, and methods of production of polypeptides using these vectors and host cells.Type: GrantFiled: December 29, 2006Date of Patent: September 6, 2011Assignee: Life Technologies CorporationInventors: Deb K. Chatterjee, Mary Longo, Elizabeth Flynn, Robert Oberfelder
-
Publication number: 20110160289Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: ApplicationFiled: May 3, 2010Publication date: June 30, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Mekbib ASTATKE, Deb K. Chatterjee, Gary F. Gerard
-
Publication number: 20110111464Abstract: The present invention is directed generally to methods facilitating the cloning of nucleic acid molecules. In particular, the invention relates to the use of polymerase inhibitors, including but not limited to anti-polymerase antibodies (such as anti-Taq antibodies) and fragments thereof, to inactivate residual polymerase activity remaining after the amplification (particularly via PCR) of a target nucleic acid molecule. The invention further provides compositions, particularly storage-stable compositions, comprising one or more components, such as one or more restriction endonucleases and one or more polymerase inhibitors, that are useful in cloning amplified or synthesized nucleic acid molecules by the above-described methods. The invention also relates to nucleic acid molecules produced by these methods, and to genetic constructs (such as vectors) and host cells comprising these nucleic acid molecules.Type: ApplicationFiled: June 8, 2010Publication date: May 12, 2011Inventors: Donna K. Fox, Deb K. Chatterjee
-
Publication number: 20110108420Abstract: The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such as E. coli thioredoxin or a modified E. coli thioredoxin, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies. The methods of the present invention facilitate the rapid isolation and purification of recombinant proteins. In addition, the present methods may be useful for producing polypeptides or proteins which are small and are typically difficult to express, as well as those proteins that are toxic to host cells such as E. coli. The present invention also provides plasmids, vectors and host cells to be used in the present invention for production of polypeptides, and methods of production of polypeptides using these vectors and host cells.Type: ApplicationFiled: January 13, 2011Publication date: May 12, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: DEB K. CHATTERJEE, Mary Longo, Elizabeth Flynn, Robert Oberfelder
-
Publication number: 20110008770Abstract: The present invention is generally related to compositions and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to compositions comprising mixtures of polypeptides having reverse transcriptase (RT) activity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these compositions or polypeptides, particularly at temperatures above about 55° C. The invention also relates to nucleic acid molecules produced by these methods, to vectors and host cells comprising these nucleic acid molecules, and to the use of such nucleic acid molecules to produce desired polypeptides.Type: ApplicationFiled: July 29, 2009Publication date: January 13, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Gary F. Gerard, Michael D. Smith, Deb K. Chatterjee